Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Glioblastoma multiforme (GBM) is a devastating tumor of the central nervous system, currently missing an effective treatment. The therapeutic gold standard consists of surgical resection followed by chemotherapy (usually with temozolomide, TMZ) and/or radiotherapy. TMZ does not, however, provide significant survival benefit after completion of treatment because of development of chemoresistance and of heavy side effects of systemic administration. Improvement of conventional treatments and complementary therapies are urgently needed to increase patient survival and quality of life. Stimuli-responsive lipid-based drug delivery systems offer promising prospects to overcome the limitations of the current treatments. In this work, multifunctional lipid-based magnetic nanovectors functionalized with the peptide angiopep-2 and loaded with TMZ (Ang-TMZ-LMNVs) were tested to enhance specific GBM therapy on an in vivo model. Exposure to alternating magnetic fields (AMFs) enabled magnetic hyperthermia to be performed, that works in synergy with the chemotherapeutic agent. Studies on orthotopic human U-87 MG-Luc2 tumors in nude mice have shown that Ang-TMZ-LMNVs can accumulate and remain in the tumor after local administration without crossing over into healthy tissue, effectively suppressing tumor invasion and proliferation and significantly prolonging the median survival time when combined with the AMF stimulation. This powerful synergistic approach has proven to be a robust and versatile nanoplatform for an effective GBM treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Smart Bio-Interfaces, Istituto Italiano di Tecnologia, Viale Rinaldo Piaggio 34, Pontedera 56025, Italy
Translational Pharmacology, Istituto Italiano di Tecnologia, Via Morego 30, Genova 16163, Italy
Funding
H2020 European Research Council
References (81)
Show source-provided references
1. 10.1016/j.jocn.2009.09.00410.1016/j.jocn.2009.09.004 ↗
2. 10.1093/neuonc/noab10610.1093/neuonc/noab106 ↗
3. 10.1158/1055-9965.EPI-14-027510.1158/1055-9965.EPI-14-0275 ↗
4. 10.1016/S1470-2045(09)70025-710.1016/S1470-2045(09)70025-7 ↗
5. 10.1080/14737175.2016.120276110.1080/14737175.2016.1202761 ↗
6. 10.1016/j.neo.2018.05.00110.1016/j.neo.2018.05.001 ↗
7. 10.1016/j.xcrm.2020.10018410.1016/j.xcrm.2020.100184 ↗
8. 10.1586/ern.10.3210.1586/ern.10.32 ↗
9. 10.1002/cncr.2374110.1002/cncr.23741 ↗
10. 10.1093/neuonc/nop04710.1093/neuonc/nop047 ↗
11. 10.1093/neuonc/5.2.7910.1093/neuonc/5.2.79 ↗
12. 10.1093/neuonc/nop05410.1093/neuonc/nop054 ↗
13. 10.1016/j.cct.2011.10.01010.1016/j.cct.2011.10.010 ↗
14. 10.2147/IJN.S14631510.2147/IJN.S146315 ↗
15. 10.1002/anbr.20200005410.1002/anbr.202000054 ↗
16. 10.1021/acs.biomac.1c0031410.1021/acs.biomac.1c00314 ↗
17. 10.1515/znc-2017-011010.1515/znc-2017-0110 ↗
18. 10.3390/cancers1315369010.3390/cancers13153690 ↗
19. 10.2147/IJN.S28622110.2147/IJN.S286221 ↗
20. 10.3389/fphar.2022.104597610.3389/fphar.2022.1045976 ↗
21. 10.1080/0265673080210475710.1080/02656730802104757 ↗
22. 10.1126/science.36465210.1126/science.364652 ↗
23. 10.1039/C9BM01880H10.1039/C9BM01880H ↗
24. 10.1016/j.jconrel.2016.05.06210.1016/j.jconrel.2016.05.062 ↗
25. 10.7150/thno.4029810.7150/thno.40298 ↗
26. 10.1021/acs.nanolett.1c0245910.1021/acs.nanolett.1c02459 ↗
27. 10.1016/S0304-8853(00)01239-710.1016/S0304-8853(00)01239-7 ↗
28. 10.1007/s11060-010-0389-010.1007/s11060-010-0389-0 ↗
29. 10.1039/C9NR03931G10.1039/C9NR03931G ↗
30. 10.1039/C8NR05520C10.1039/C8NR05520C ↗
31. 10.1039/C9NR07976A10.1039/C9NR07976A ↗
32. 10.1021/acsami.0c0555610.1021/acsami.0c05556 ↗
33. 10.1021/acsami.0c1290010.1021/acsami.0c12900 ↗
34. 10.1021/acsami.8b1827010.1021/acsami.8b18270 ↗
35. 10.1080/0265673041000170318610.1080/02656730410001703186 ↗
36. 10.1080/10717544.2018.146128010.1080/10717544.2018.1461280 ↗
37. 10.1016/j.cej.2019.05.05510.1016/j.cej.2019.05.055 ↗
38. 10.1039/C9TB02470K10.1039/C9TB02470K ↗
39. 10.1124/jpet.107.13131810.1124/jpet.107.131318 ↗
40. 10.1111/j.1471-4159.2008.05492.x10.1111/j.1471-4159.2008.05492.x ↗
41. 10.1016/j.jconrel.2017.11.02610.1016/j.jconrel.2017.11.026 ↗
42. 10.1021/acsami.9b0831810.1021/acsami.9b08318 ↗
43. 10.1021/acsanm.2c0322010.1021/acsanm.2c03220 ↗
44. 10.1080/0265673060117547910.1080/02656730601175479 ↗
45. 10.3109/0265673100374574010.3109/02656731003745740 ↗
46. 10.1109/TBME.2013.229623110.1109/TBME.2013.2296231 ↗
47. 10.1016/j.jmmm.2006.10.115610.1016/j.jmmm.2006.10.1156 ↗
48. 10.3109/02656736.2013.82299310.3109/02656736.2013.822993 ↗
49. 10.3109/0265673930906147810.3109/02656739309061478 ↗
50. Beola L. · 2019 · 31710.1016/B978-0-12-813928-8.00012-0 ↗
51. 10.1038/s41598-017-12563-510.1038/s41598-017-12563-5 ↗
52. 10.7150/thno.4978710.7150/thno.49787 ↗
53. 10.1016/j.nano.2014.09.00510.1016/j.nano.2014.09.005 ↗
54. 10.1007/s11912-019-0783-510.1007/s11912-019-0783-5 ↗
55. 10.1021/acsami.1c0233810.1021/acsami.1c02338 ↗
56. 10.1007/s00280-010-1305-110.1007/s00280-010-1305-1 ↗
57. 10.1002/ijc.2106110.1002/ijc.21061 ↗
58. 10.1039/D0NR05053A10.1039/D0NR05053A ↗
59. 10.1016/j.jconrel.2016.04.00610.1016/j.jconrel.2016.04.006 ↗
60. 10.1021/acsnano.2c1009410.1021/acsnano.2c10094 ↗
61. 10.1021/acsami.8b0239810.1021/acsami.8b02398 ↗
62. 10.1080/01616412.1997.1174087410.1080/01616412.1997.11740874 ↗
63. 10.1007/s11060-014-1459-510.1007/s11060-014-1459-5 ↗
64. 10.1007/s11060-015-1875-110.1007/s11060-015-1875-1 ↗
65. 10.1215/15228517-2006-00710.1215/15228517-2006-007 ↗
66. 10.1016/j.mtbio.2022.10048410.1016/j.mtbio.2022.100484 ↗
67. 10.1021/acsnano.8b0620110.1021/acsnano.8b06201 ↗
68. 10.14670/HH-24.87910.14670/HH-24.879 ↗
69. 10.1080/10717544.2016.118946510.1080/10717544.2016.1189465 ↗
70. 10.1093/neuonc/noz04810.1093/neuonc/noz048 ↗
71. 10.1038/nrc207310.1038/nrc2073 ↗
72. 10.1007/s11060-012-0807-610.1007/s11060-012-0807-6 ↗
73. 10.1111/ejn.1200710.1111/ejn.12007 ↗
74. 10.1016/j.jneuroim.2019.04.00510.1016/j.jneuroim.2019.04.005 ↗
75. 10.2147/IJN.S5750110.2147/IJN.S57501 ↗
76. 10.1080/02656736.2018.143086710.1080/02656736.2018.1430867 ↗
77. 10.1016/j.bcp.2013.06.02010.1016/j.bcp.2013.06.020 ↗
78. 10.1158/0008-5472.CAN-20-037310.1158/0008-5472.CAN-20-0373 ↗
79. 10.1038/nrc326110.1038/nrc3261 ↗
80. 10.1016/j.ccr.2013.04.01710.1016/j.ccr.2013.04.017 ↗
81. 10.1016/j.mtbio.2021.10019610.1016/j.mtbio.2021.100196 ↗